CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of spinal muscular atrophy
3.4.1.2. Initiatives by government organizations
3.4.1.3. Increase in the demand for drugs for the SMA
3.4.2. Restraints
3.4.2.1. High cost of SMA drugs
3.4.3. Opportunities
3.4.3.1. Increase in R&D activities
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Type 1
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Type 2
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Parenteral
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Others
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
CHAPTER 7: SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Type
7.2.3. Market size and forecast, by Route of Administration
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Type
7.2.5.1.3. Market size and forecast, by Route of Administration
7.2.5.1.4. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Type
7.2.5.2.3. Market size and forecast, by Route of Administration
7.2.5.2.4. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Type
7.2.5.3.3. Market size and forecast, by Route of Administration
7.2.5.3.4. Market size and forecast, by End User
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Type
7.3.3. Market size and forecast, by Route of Administration
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Type
7.3.5.1.3. Market size and forecast, by Route of Administration
7.3.5.1.4. Market size and forecast, by End User
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Type
7.3.5.2.3. Market size and forecast, by Route of Administration
7.3.5.2.4. Market size and forecast, by End User
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Type
7.3.5.3.3. Market size and forecast, by Route of Administration
7.3.5.3.4. Market size and forecast, by End User
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Type
7.3.5.4.3. Market size and forecast, by Route of Administration
7.3.5.4.4. Market size and forecast, by End User
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Type
7.3.5.5.3. Market size and forecast, by Route of Administration
7.3.5.5.4. Market size and forecast, by End User
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Type
7.3.5.6.3. Market size and forecast, by Route of Administration
7.3.5.6.4. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Type
7.4.3. Market size and forecast, by Route of Administration
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Type
7.4.5.1.3. Market size and forecast, by Route of Administration
7.4.5.1.4. Market size and forecast, by End User
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Type
7.4.5.2.3. Market size and forecast, by Route of Administration
7.4.5.2.4. Market size and forecast, by End User
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Type
7.4.5.3.3. Market size and forecast, by Route of Administration
7.4.5.3.4. Market size and forecast, by End User
7.4.5.4. Australia
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Type
7.4.5.4.3. Market size and forecast, by Route of Administration
7.4.5.4.4. Market size and forecast, by End User
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Type
7.4.5.5.3. Market size and forecast, by Route of Administration
7.4.5.5.4. Market size and forecast, by End User
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Type
7.4.5.6.3. Market size and forecast, by Route of Administration
7.4.5.6.4. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Type
7.5.3. Market size and forecast, by Route of Administration
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Latin America
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Type
7.5.5.1.3. Market size and forecast, by Route of Administration
7.5.5.1.4. Market size and forecast, by End User
7.5.5.2. Middle East And Africa
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Type
7.5.5.2.3. Market size and forecast, by Route of Administration
7.5.5.2.4. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Biogen
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Cytokinetics
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Hanugen Theraputics
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.4. NMD Phrama A/S
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Key strategic moves and developments
9.5. Novartis AG
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. F. Hoffmann-La Roche Ltd.
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Pfizer Inc.
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Scholar Rock Holding Corporation
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Beijing Jinlan Gene Technology Co., Ltd.
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Key strategic moves and developments
9.10. Ionis Pharmaceuticals, Inc.
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments
TABLE 01. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 02. SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR TYPE 1, BY REGION, 2022-2032 ($MILLION)
TABLE 03. SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR TYPE 2, BY REGION, 2022-2032 ($MILLION)
TABLE 04. SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 06. SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
TABLE 07. SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR PARENTERAL, BY REGION, 2022-2032 ($MILLION)
TABLE 08. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 09. SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
TABLE 10. SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 12. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 13. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 16. U.S. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 17. U.S. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 18. U.S. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 19. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 20. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 21. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 22. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 23. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 24. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 25. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 26. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 27. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 28. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 29. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 30. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 31. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 32. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 33. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 34. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 35. UK SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 36. UK SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 37. UK SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 38. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 39. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 40. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 41. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 42. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 43. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 44. REST OF EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 45. REST OF EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 46. REST OF EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 47. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 48. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 49. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 51. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 52. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 53. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 54. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 55. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 56. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 57. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 58. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 59. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 60. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 61. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 62. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 63. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 64. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 65. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 66. REST OF ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 67. REST OF ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 69. LAMEA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 70. LAMEA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 71. LAMEA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 72. LAMEA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 73. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 74. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 75. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 76. MIDDLE EAST AND AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 77. MIDDLE EAST AND AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 78. MIDDLE EAST AND AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 79. BIOGEN: KEY EXECUTIVES
TABLE 80. BIOGEN: COMPANY SNAPSHOT
TABLE 81. BIOGEN: PRODUCT SEGMENTS
TABLE 82. BIOGEN: PRODUCT PORTFOLIO
TABLE 83. CYTOKINETICS: KEY EXECUTIVES
TABLE 84. CYTOKINETICS: COMPANY SNAPSHOT
TABLE 85. CYTOKINETICS: PRODUCT SEGMENTS
TABLE 86. CYTOKINETICS: PRODUCT PORTFOLIO
TABLE 87. HANUGEN THERAPUTICS: KEY EXECUTIVES
TABLE 88. HANUGEN THERAPUTICS: COMPANY SNAPSHOT
TABLE 89. HANUGEN THERAPUTICS: PRODUCT SEGMENTS
TABLE 90. HANUGEN THERAPUTICS: PRODUCT PORTFOLIO
TABLE 91. NMD PHRAMA A/S: KEY EXECUTIVES
TABLE 92. NMD PHRAMA A/S: COMPANY SNAPSHOT
TABLE 93. NMD PHRAMA A/S: PRODUCT SEGMENTS
TABLE 94. NMD PHRAMA A/S: PRODUCT PORTFOLIO
TABLE 95. NMD PHRAMA A/S: KEY STRATERGIES
TABLE 96. NOVARTIS AG: KEY EXECUTIVES
TABLE 97. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 98. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 99. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 100. NOVARTIS AG: KEY STRATERGIES
TABLE 101. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 102. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 103. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 104. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 105. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
TABLE 106. PFIZER INC.: KEY EXECUTIVES
TABLE 107. PFIZER INC.: COMPANY SNAPSHOT
TABLE 108. PFIZER INC.: PRODUCT SEGMENTS
TABLE 109. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 110. SCHOLAR ROCK HOLDING CORPORATION: KEY EXECUTIVES
TABLE 111. SCHOLAR ROCK HOLDING CORPORATION: COMPANY SNAPSHOT
TABLE 112. SCHOLAR ROCK HOLDING CORPORATION: PRODUCT SEGMENTS
TABLE 113. SCHOLAR ROCK HOLDING CORPORATION: PRODUCT PORTFOLIO
TABLE 114. SCHOLAR ROCK HOLDING CORPORATION: KEY STRATERGIES
TABLE 115. BEIJING JINLAN GENE TECHNOLOGY CO., LTD.: KEY EXECUTIVES
TABLE 116. BEIJING JINLAN GENE TECHNOLOGY CO., LTD.: COMPANY SNAPSHOT
TABLE 117. BEIJING JINLAN GENE TECHNOLOGY CO., LTD.: PRODUCT SEGMENTS
TABLE 118. BEIJING JINLAN GENE TECHNOLOGY CO., LTD.: PRODUCT PORTFOLIO
TABLE 119. BEIJING JINLAN GENE TECHNOLOGY CO., LTD.: KEY STRATERGIES
TABLE 120. IONIS PHARMACEUTICALS, INC.: KEY EXECUTIVES
TABLE 121. IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 122. IONIS PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
TABLE 123. IONIS PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
TABLE 124. IONIS PHARMACEUTICALS, INC.: KEY STRATERGIES
